지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2011.1
- 수록면
- 128 - 136 (9page)
이용수
초록· 키워드
오류제보하기
Background and Purpose Levetiracetam (LEV) is a new antiepileptic drug that has been found to be effective as an adjunctive therapy for uncontrolled partial seizures. However, the results of several studies suggested that LEV has negative psychotropic effects, including irritability, aggressiveness, suicidality, and mood disorders. We investigated the impact of adjunctive LEV on psychiatric symptoms and quality of life (QOL) in patients with drug-refractory epilepsy (DRE) and determined the risk factors provoking psychiatric adverse events.
Methods A 24-week, prospective, open-label study was conducted. At enrollment, we interviewed patients and reviewed their medical charts to collect demographic and clinical information. They were asked to complete self-report health questionnaires designed to measure various psychiatric symptoms and QOL at enrollment and 24 weeks later.
Results Seventy-one patients were included in the study, 12 patients (16.9%) of whom discontinued LEV therapy due to serious adverse events including suicidality. The risk factor for premature withdrawal was a previous history of psychiatric diseases (odds ratio 4.59; 95% confidence interval, 1.22-17.32). LEV intake resulted in significant improvements in Beck Anxiety Inventory score (p<0.01) and some domains of the Symptom Checklist-90-Revised, such as somatization (p<0.05), obsessive-compulsiveness (p<0.05), depression (p<0.05), and anxiety (p<0.05). These improvements were not related to the occurrence of seizure freedom. The Quality of Life in Epilepsy Inventory-31 overall score and subscale scores, such as seizure worry (p<0.01),overall QOL (p<0.05), emotional well-being (p<0.05), energy-fatigue (p<0.05), and social function (p<0.05), also improved.
Conclusions Adjunctive LEV in patients with DRE is likely to improve psychiatric symptoms and QOL. Clinicians should be well aware of the psychiatric histories of patients to prevent them from developing serious adverse events related to LEV.
목차
등록된 정보가 없습니다.
참고문헌 (24)
참고문헌 신청
Baker GA / 1997 / Quality of life of people with epilepsy: a European study / Epilepsia 38 : 353 ~ 362
Berg AT / 2001 / Early development of intractable epilepsy in children: a prospective study / Neurology 56 : 1445 ~ 1452
Bootsma HP / 2007 / Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center / Epilepsy Behav 10
Cereghino JJ / 2000 / Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial / Neurology 55 : 236 ~ 242
Ciesielski AS / 2006 / Neuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: a comparative short-term study / Epilepsy Behav 9 :
Berg AT / 2001 / Early development of intractable epilepsy in children: a prospective study / Neurology 56 : 1445 ~ 1452
Bootsma HP / 2007 / Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center / Epilepsy Behav 10
Cereghino JJ / 2000 / Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial / Neurology 55 : 236 ~ 242
Ciesielski AS / 2006 / Neuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: a comparative short-term study / Epilepsy Behav 9 :
이 논문의 저자 정보
최근 본 자료
댓글(0)
0